Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYOS Vet is a veterinary-exclusive nutraceutical supplement developed by MYOS Corporation to support muscle health and mitigate muscle loss in animals, including dogs, cats, and horses. Its primary active ingredient is Fortetropin, a proprietary, non-thermally processed fertilized egg yolk powder. Fortetropin acts by reducing circulating levels of myostatin, a protein that inhibits muscle growth, while simultaneously activating the mTOR pathway to promote muscle protein synthesis and downregulating the ubiquitin-proteasome pathway to reduce muscle protein degradation. It is clinically utilized to address sarcopenia (age-related muscle loss), support recovery from orthopedic surgery (such as CCL repair), and improve mobility in geriatric or injured veterinary patients. The product line includes specialized formulations such as Vet Strength, which includes branched-chain amino acids (BCAAs), and MYOS PLUS, which incorporates joint support ingredients like green-lipped mussel and eggshell membrane.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MYOS Vet.